ReviewJournal of biological methods2025
Survival outcomes in patients with stages I-III gastric adenocarcinoma treated with surgery alone versus surgery plus adjuvant chemotherapy: A systematic review.
Review in Journal of biological methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Learning from an Emerging Infection: How the COVID-19 Pandemic Reshaped Gastric Cancer Care.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric adenocarcinoma, the malignant proliferation of glandular cells in stomach epithelium, is a type of gastric cancer with a statistical disease burden of the fifth most common cancer globally and the 17 Objective: The study reviewed patients with stages I-III (non-advanced) gastric adenocarcinoma to assess whether adjuvant chemotherapy combined with surgery provides better disease-free/disease-specific/cause-specific survival, overall survival, and reduced recurrence rates/improved recurrence-free survival, compared to surgery alone. Analyzed were 17 English-language, full-text, levels I-III peer-reviewed studies from MEDLINE and Embase from the past 10 years were analyzed. No age/sex/ethnicity/country restrictions were applied, and the dimension of interest was limited to stages I-III gastric adenocarcinoma patients who underwent tumor resection through surgery and received chemotherapy as the only adjuvant therapy. Seven (41.2%) studies have more than one statistically significant outcome measure supporting the benefit of adjuvant chemotherapy in combination with surgery over surgery alone. Ten (58.8%) studies showed no statistically significant benefit of adjuvant chemotherapy. Conclusion: The findings contrasted with previous large-scale meta-analyses, which were limited by sample size and biases in individual studies reviewed. Continued research, incorporating advances in surgical techniques and new chemotherapeutic combinations, is necessary to ascertain best-tailored treatments for gastric adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.